HSV-1,2 (IgG) w Rflx to HSV-2 Inhib HSV12IN

Synonyms
Allscripts (AEHR) Order Name	HSV-1,2 (IgG) w Rflx to HSV-2 Inhib
Sunrise Clinical Manager (SCM) Order Name	Not Orderable
EPIC Order Name	HSV-1,2 (IgG) w Rflx to HSV-2 Inhib
Clinical Info	Herpes Simplex Virus 1 and 2 (IgG), with Reflex to HSV-2 Inhibition - Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningoencephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related antigenically. HSV type 2 is more commonly associated with genital tract and neonatal infections, while HSV type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients.
Specimen Type	Blood
Container	Gold Top Tube
Collection Instructions	Container/Tube: Gold Top Tube Specimen: 2 mL serum (1 mL min) Transport Temperature: Room Temperature Stability: 7 Days Room Temperature 14 Days Refrigerated 30 Days Frozen
Transport Instructions	Room Temperature
Specimen Stability	7 Days Room Temperature 14 Days Refrigerated 30 Days Frozen
Methodology	Immunoassay (IA)
Days Performed	TAT: 2 - 3 Days
Performing Laboratory	Quest Diagnostics Nichols Institute, Chantilly, VA Herpes Simplex Virus 2 (IgG) is >1.09, then HSV-2 Inhibition Study will be performed at an additional charge (CPT code(s): 86696).
CPT	86695 86696
PDM	2159704
Result Interpretation
Forms